About David Miller, MD, PhD

David M. Miller, MD, PhD is a board-certified Internist, Dermatologist and Medical Oncologist.

Dr. Miller graduated with Honors from Boston College where he earned a BA in Political Science. He received his medical (MD) and PhD degree in Biomedical Sciences from the University of Massachusetts. While at UMass, Dr. Miller received the American Diabetes Association Physician-Scientist Training Award, a Fuller Foundation grant, and he was inducted into the Alpha Omega Honor Society. He then completed a Dermatology residency at Columbia University Medical Center, followed by a residency in Internal Medicine at Brigham and Women's Hospital. Following both residencies, Dr. Miller completed fellowship training in Hematology/Oncology at Beth Israel Deaconess Medical Center and in the Oncology Center of Excellence at the Food and Drug Administration (FDA).

Dr. Miller is one of the very few clinicians in the entire country who is board certified in Internal Medicine, Dermatology and Medical Oncology. He currently practices both Dermatology and Medical Oncology in the MGH Cancer Center and at Massachusetts Eye and Ear Infirmary, where he co-directs multidisciplinary clinics in advanced skin cancer.

Dr. Miller belongs to several professional organizations, including the American Academy of Dermatology, (AAD) Medical Dermatology Society, and the American Society of Clinical Oncology. He has numerous peer-reviewed publications and he has presented his work at the Society for Investigative Dermatology, New York Academy of Medicine, the AAD, the Merkel Cell Carcinoma Interest Group, the International Symposium on Merkel Cell Carcinoma, and the FDA. Dr. Miller has also been invited to a give a Visiting Professor Lectureship at the University of Nebraska. He is also a reviewer for the British Journal of Dermatology, Journal of Investigative Dermatology, JAEDV, and Clinical Cancer Research.

Departments, Centers, & Programs:

Clinical Interests:



Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130

Medical Education

  • PhD, University of Massachusetts Medical School
  • Residency, Brigham and Women's Hospital
  • Residency, Columbia University Medical Center
  • Residency, New York Presbyterian Hospital
  • Fellowship, Beth Israel Deaconess Hospital

American Board Certifications

  • Dermatology, American Board of Dermatology
  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Miller's research is focused on developing novel therapies for advanced skin cancer. He has received support for his research from the NIH in the form of a loan repayment award, a Research Grant from the American Skin Association, the Paul Carbone, MD fellowship award from ECOG-ACRIN, and the Mentoring Award in Oncology, Advanced Analytics and Regulatory Science from Project Data Sphere. You can find out more about Dr. Miller's research at https://www.themillerlab.io.


  • Select Publications:

    • Eliades P, Abraham B, Ji Z, Miller DM, et al. High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma. Journal Investigative Dermatology. 2018 Feb 2
    • Miller DM, et al. Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. JAAD Case Reports. 2017 Sep 8;3(5):412-415
    • Reddy B, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 2017 Jun 1;123(S11):2104-2117
    • Eliades P*, Miller DM*, et al. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biol Ther. 2016 Jul 2;17(7):778-784.
    • Miller DM, Flaherty KT, Tsao H. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Seminars in Cutaneous Medicine and Surgery. 2014 Jun;33(2):60-7
    • Miller DM, Flaherty KT, Tsao H. Molecular Testing in Melanoma. Journal of the American Academy of Dermatology;2014 May;70(5):863-870
    • Miller DM, Flaherty KT. Cyclin-dependent kinases as therapeutic targets in melanoma. Pigment Cell and Melanoma Research; 2014 May;27(3):351-365

Reviews: Comments and Ratings